BTK and B-cell chronic lymphocytic leukemia: Otherwise, ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, improved engraftment of CAR T cells, tumor clearance, and survival in human or xenografts models of BTK-resistant acute and chronic lymphocytic leukemia [40,41,42,43].